Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 7 |
| 1.1 List of Tables | 6 | 2 |
| 1.2 List of Figures | 8 | 2 |
| Global Diabetes Market: Introduction | 10 | 1 |
| 2.1 GBI Research Report Guidance | 10 | 1 |
| Global Diabetes Market: Market Overview | 11 | 12 |
| 3.1 Introduction | 11 | 1 |
| 3.2 Unmet Needs | 11 | 1 |
| 3.2.1 Heart Risks Associated with some of the Oral Anti-diabetic Drugs | 11 | 1 |
| Carcinogenic Effects Associated With Insulin Analogs | 12 | 1 |
| 3.2.3 Poor Patient Compliance | 12 | 1 |
| 3.3 Revenue | 12 | 2 |
| 3.4 Annual Cost of Therapy | 14 | 1 |
| 3.5 Treatment Usage Patterns | 15 | 2 |
| 3.5.1 Diseased Population | 17 | 1 |
| 3.5.2 Treatment Seeking Population | 18 | 1 |
| 3.5.3 Diagnosed Population | 19 | 1 |
| 3.5.4 Prescription Population | 20 | 1 |
| 3.6 Drivers and Restraints of Diabetes Market | 21 | 1 |
| 3.6.1 Drivers of Diabetes Market | 21 | 1 |
| 3.6.1.1 First-in-class Drugs in the pipeline | 21 | 1 |
| 3.6.1.2 Increase in Prescription of Peptide Analogs | 21 | 1 |
| 3.6.1.3 Sedentary Lifestyles and Obesity to increase Diabetes Prevalence | 21 | 1 |
| 3.6.1.4 Increase in Prevalence and Treatment Seeking | 21 | 1 |
| 3.6.2 Restraints of Diabetes Market | 21 | 1 |
| 3.6.2.1 Side Effects Affecting Prescription Sales of Diabetes Drugs | 21 | 1 |
| 3.6.2.2 Patent Expiries of Drugs such as Actos, Starlix and Avandia are Expected to Restrain the Growth of the Global Diabetes Therapeutics Market | 22 | 1 |
| 4 Global Diabetes Market: Geographical Landscape | 23 | 25 |
| 4.1 The US | 25 | 1 |
| Revenue | 25 | 2 |
| 4.1.2 Annual Cost of Therapy | 27 | 1 |
| 4.1.3 Treatment Usage Patterns | 28 | 1 |
| 4.1.3.1 Diseased Population | 29 | 1 |
| 4.1.3.2 Treatment Seeking Population | 30 | 1 |
| 4.1.3.3 Diagnosis Population | 31 | 1 |
| 4.1.3.4 Prescription Population | 32 | 1 |
| 4.2 Top Five EU Countries | 33 | 1 |
| Revenue | 33 | 2 |
| 4.2.2 Annual Cost of Therapy | 35 | 1 |
| 4.2.3 Treatment Usage Patterns | 36 | 1 |
| 4.2.3.1 Diseased Population | 37 | 1 |
| 4.2.3.2 Treatment Seeking Population | 38 | 1 |
| 4.2.3.3 Diagnosis Population | 39 | 1 |
| 4.2.3.4 Prescription Population | 40 | 1 |
| 4.3 Japan | 41 | 1 |
| Revenue | 41 | 1 |
| 4.3.2 Annual Cost Therapy | 42 | 1 |
| 4.3.3 Treatment Usage Patterns | 43 | 1 |
| 4.3.3.1 Diseased Population | 44 | 1 |
| 4.3.3.2 Treatment Seeking Population | 45 | 1 |
| 4.3.3.3 Diagnosis Population | 46 | 1 |
| 4.3.3.4 Prescription Population | 47 | 1 |
| 5 Global Diabetes Market: Therapeutic Landscape | 48 | 29 |
| 5.1 Type 1 Diabetes Market | 48 | 1 |
| 5.1.1 Introduction | 48 | 1 |
| 5.1.2 Symptoms | 48 | 1 |
| 5.1.3 Treatment | 48 | 2 |
| 5.1.4 Unmet need | 50 | 1 |
| 5.1.5 Revenue | 51 | 1 |
| Annual Cost of therapy | 52 | 2 |
| 5.1.7 Treatment Usage Patterns | 54 | 2 |
| 5.1.7.1 Diseased Population | 56 | 1 |
| 5.1.7.2 Treatment Seeking Population | 57 | 1 |
| 5.1.7.3 Diagnosis Population | 58 | 1 |
| 5.1.7.4 Prescription Population | 59 | 1 |
| 5.1.8 Drivers and Restraints for the Type 1 Diabetes Market | 60 | 1 |
| 5.1.8.1 Drivers for the Type 1 Diabetes Market | 60 | 1 |
| 5.1.8.2 Restraints for the Type 1 Diabetes Market | 61 | 1 |
| 5.2 Type 2 diabetes Therapeutics Market | 61 | 1 |
| 5.2.1 Introduction | 61 | 1 |
| 5.2.2 Symptoms | 61 | 1 |
| 5.2.3 Treatment | 62 | 1 |
| 5.2.4 Unmet need | 62 | 1 |
| 5.2.5 Revenue | 63 | 1 |
| 5.2.6 Annual Cost of therapy | 64 | 2 |
| 5.2.7 Treatment Usage Patterns | 66 | 2 |
| 5.2.7.1 Diseased Population | 68 | 1 |
| 5.2.7.2 Treatment Seeking Population | 69 | 1 |
| 5.2.7.3 Diagnosis Population | 70 | 1 |
| 5.2.7.4 Prescription Population | 71 | 1 |
| 5.2.8 Drivers and Restraints for the Type 2 Diabetes Market | 72 | 1 |
| 5.2.8.1 Drivers for Type 2 Diabetes Market | 72 | 1 |
| 5.2.8.2 Restraints for Type 2 Diabetes Market | 72 | 2 |
| 5.3 Revenues by Class of Drugs of Type 2 Diabetes | 74 | 3 |
| 6 Global Diabetes Market: Pipeline Analysis | 77 | 29 |
| Introduction | 77 | 2 |
| 6.1.1 Research and Development Pipeline Type 1 Diabetes | 79 | 4 |
| 6.1.2 Research and Development Pipeline Type 2 Diabetes | 83 | 11 |
| 6.2 Innovations in Diabetes Treatment | 94 | 1 |
| 6.2.1 Insulin in Pills (Oral Delivery) | 94 | 1 |
| 6.2.2 Promising Treatments for Diabetic Retinopathy | 94 | 1 |
| 6.2.3 Biomarkers in Diabetes | 94 | 1 |
| 6.2.4 Combination Drugs are an Important Part of the Diabetes Therapeutics Pipeline | 94 | 1 |
| 6.3 Drug Delivery in Diabetes | 95 | 1 |
| 6.3.1 Factors Determining Preference for Drug Delivery | 95 | 1 |
| 6.3.2 Desirable Drug Delivery Methods for Diabetes are Currently Unavailable | 95 | 1 |
| 6.3.3 Innovation in Drug Delivery Systems | 96 | 1 |
| 6.3.3.1 Transdermal Passport System | 96 | 1 |
| 6.3.3.2 Encapsulation System s U-Strip Insulin System | 96 | 1 |
| 6.3.3.3 Technosphere/Insulin | 96 | 1 |
| 6.4 Profiles of Promising Drugs in the Diabetes Market | 97 | 1 |
| 6.4.1 rhGAD65 (Diamyd) | 97 | 1 |
| 6.4.2 DiaPep277 | 97 | 1 |
| 6.4.3 Otelixizumab | 98 | 1 |
| 6.4.4 Oral-lyn | 99 | 1 |
| 6.4.5 BMS-512148 (dapagliflozin) | 100 | 1 |
| 6.4.6 Victoza (liraglutide) | 101 | 2 |
| 6.4.7 D-Tagatose | 103 | 1 |
| 6.4.8 JNJ-28431754 (canagliflozin) | 103 | 1 |
| 6.4.9 MB07803 | 104 | 2 |
| 7 Global Diabetes Market: Competitive Landscape | 106 | 35 |
| 7.1 Diabetes Market Overview | 106 | 1 |
| 7.1.1 Human Insulin Products and Oral Anti-diabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth | 106 | 1 |
| 7.2 Market Share Analysis: Diabetes | 107 | 1 |
| 7.3 Competitive Profiling | 108 | 1 |
| 7.3.1 Novo Nordisk | 109 | 2 |
| 7.3.1.1 Product Portfolio | 111 | 1 |
| 7.3.1.2 Marketed Drugs Profile | 112 | 2 |
| 7.3.1.3 Product Pipeline | 114 | 1 |
| 7.3.1.4 SWOT Analysis | 115 | 1 |
| 7.3.2 Sanofi-Aventis | 116 | 1 |
| 7.3.2.1 Product Portfolio | 117 | 1 |
| 7.3.2.2 Marketed Drugs profiles | 118 | 2 |
| 7.3.2.3 Product Pipeline | 120 | 1 |
| 7.3.2.4 SWOT Analysis | 120 | 1 |
| 7.3.3 Takeda | 121 | 1 |
| 7.3.3.1 Product Portfolio | 121 | 1 |
| 7.3.3.2 Marketed Drugs Profiles | 122 | 1 |
| 7.3.3.3 Product Pipeline | 123 | 1 |
| 7.3.3.4 SWOT Analysis | 123 | 1 |
| 7.3.4 Eli Lilly | 124 | 1 |
| 7.3.4.1 Product Portfolio | 125 | 1 |
| 7.3.4.2 Marketed Drug Profiles | 126 | 2 |
| 7.3.4.3 Product Pipeline | 128 | 1 |
| 7.3.4.4 SWOT Analysis | 129 | 1 |
| 7.3.5 GlaxoSmithKline (GSK) | 130 | 1 |
| 7.3.5.1 Product Portfolio | 131 | 1 |
| 7.3.5.2 Marketed Drugs Profiles | 131 | 2 |
| 7.3.5.3 Product Pipeline | 133 | 1 |
| 7.3.5.4 SWOT Analysis | 133 | 1 |
| 7.3.6 Merck &Co Inc | 134 | 1 |
| 7.3.6.1 Product Portfolio | 135 | 1 |
| 7.3.6.2 Marketed Drugs Profle | 135 | 1 |
| 7.3.6.3 Product Pipeline | 136 | 1 |
| 7.3.6.4 SWOT Analysis | 136 | 1 |
| 7.3.7 Amylin Pharmaceuticals | 137 | 1 |
| 7.3.7.1 Product Portfolio | 138 | 1 |
| 7.3.7.2 Marketed Drugs Profiles | 138 | 1 |
| 7.3.7.3 Product Pipeline | 139 | 1 |
| 7.3.7.4 SWOT Analysis | 140 | 1 |
| 8 Global Diabetes Market: M&A Landscape | 141 | 6 |
| Overview | 141 | 1 |
| 8.1.1 M&A by Geography | 142 | 1 |
| 8.1.2 M&A by Value ($) | 143 | 1 |
| 8.2 R&D Licensing Agreements | 143 | 2 |
| 8.2.1 Deals by Geography | 145 | 1 |
| 8.2.2 Deals by Value ($) | 146 | 1 |
| 9 Global Diabetes Market: Appendix | 147 | 7 |
| 9.1 Market Definitions | 147 | 1 |
| 9.2 Abbreviations | 147 | 2 |
| 9.3 Research Methodology | 149 | 4 |
| 9.3.1 Coverage | 149 | 1 |
| 9.3.2 Secondary Research | 149 | 1 |
| 9.3.3 Primary Research | 149 | 1 |
| 9.3.4 Forecasts | 150 | 1 |
| 9.3.4.1 Epidemiology-based Forecasting | 150 | 2 |
| 9.3.5 Expert Panel Validation | 152 | 1 |
| 9.4 Contact Us | 153 | 1 |
| 9.5 Disclaimer | 153 | 1 |
| 9.6 Sources | 153 | 1 |